371P System dynamics analysis of access pathways and hurdles for ctDNA-based MRD testing in solid tumors

Table: 369P 336 FHC ratio 1 st degree Mean 0.39 (0-1.44)Median 0.35 (0-0.61)FHC ratio 2 nd degree Mean 0.03 (0-0.25)Median 0 (0-0.06)FHC ratio 3 rd degree Mean 0.01 (0-0.15)Median 0 (0-0.02)Total FHC score Mean 0.43 (0-1.48)Median 0.40 (0.12-0.67) 90 th percentile threshold 0.89 (0.62-0.96) 75 th percentile threshold 0.67 (0.62-0.71)Patients included 90 th percentile 33 (9.8%)Patients included 75 th percentile 83 (24.7%) Conclusions:The observational phase of the study shows the potential utility of FHC in selecting NSCLC patients for germline mutation testing.Clinical trial identification: NCT06196424.